AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
RWJBarnabas Health research were awarded a $2.4 million grant to develop technology to better manage patients presenting with heart attacks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback